(Reuters Health) - Weight loss surgery may be a cost-effective way of lowering blood sugar for many diabetics, not just those who are severely obese, a Swedish study suggests.
Researchers found that for people with diabetes, total healthcare costs did not rise in the years following weight-loss surgery, largely because of overall savings from less use of healthcare and medications.
For people with normal or merely elevated blood sugar below the cut-off for diabetes, the surgery was linked to higher costs afterward.
Left untreated, diabetes can lead to nerve damage, amputations, blindness, heart disease and strokes.
A growing number of extremely obese patients have turned to surgery after failing to achieve significant weight loss through diet, exercise or medication – strategies that can also manage diabetes. Like all surgery, it isn’t risk free, and bariatric operations in particular carry a risk of malnutrition.
Clinical guidelines used in many parts of the world only recommend bariatric surgery for patients who are extremely obese, based on a measure of weight relative to height known as body mass index (BMI).
An obese adult who is 5 feet 9 inches tall would weigh at least 203 pounds and have a BMI of 30 or more, for example. Only adults with a BMI greater than 40 should get bariatric surgery, according to widely followed recommendations from the U.S. National Institutes of Health, although some patients with serious health problems, including diabetes, may be candidates with a BMI over 35.
For the current study, Neovius and colleagues followed 4,030 patients for about 15 years. Roughly half of them received bariatric surgery, while the rest did not.
Within each group at the start of the study, many patients didn’t have diabetes, while some had elevated blood sugar that suggested they might be at risk for developing the disease and others already had full-blown diabetes.
When people without full-blown diabetes got bariatric surgery, their treatment costs including the operations and follow-up care were higher than similar patients who didn’t have the procedures.
But for diabetics, the costs for the surgery group and the nonsurgical group were roughly the same after 15 years. The cost of surgery was largely offset by less use of healthcare and lower prescription drug costs, the study found.
One limitation of the study is that it relied in part on self-reported drug costs, and lacked data on costs related to nonprescription drugs, nursing homes, medical equipment and certain services like dieticians and psychologists, the authors acknowledge in The Lancet Diabetes and Endocrinology.
The findings suggest that bariatric surgery should be considered for diabetics who don’t succeed at controlling their blood sugar with drugs and lifestyle changes, regardless of their BMI, argues Ricardo Cohen, of the Center for Obesity and Diabetes at the Hospital Oswaldo Cruz in Sao Paulo, Brazil, in an accompanying editorial.
Bariatric surgery guidelines should be “unchained from BMI alone,” Cohen told Reuters Health in an email. “Patients should not have any barrier to the surgical treatment of diabetes when there are several studies that show when diabetes is not under control with medication, surgery offers good clinical and outcomes.”
From reuters health
Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study
Bariatric surgery prevents and induces remission of type 2 diabetes in many patients. The effect of preoperative glucose status on long-term health-care costs is unknown. We aimed to assess health-care costs over 15 years for patients with obesity treated conventionally or with bariatric surgery and who had either euglycaemia, prediabetes, or type 2 diabetes before intervention.
The Swedish Obese Subjects (SOS) study is a prospective study of adults who had bariatric surgery and contemporaneously matched controls who were treated conventionally (age 37–60 years; BMI of ≥34 in men and ≥38 in women) recruited from 25 Swedish surgical departments and 480 primary health-care centres. Exclusion criteria were identical for both study groups, and were previous gastric or bariatric surgery, recent malignancy or myocardial infarction, selected psychiatric disorders, and other contraindicating disorders to bariatric surgery. Conventional treatment ranged from no treatment to lifestyle intervention and behaviour modification. In this study, we retrieved prescription drug costs for the patients in the SOS study via questionnaires and the nationwide Swedish Prescribed Drug Register. We retrieved data for inpatient and outpatient visits from the Swedish National Patient Register. We followed up the sample linked to register data for up to 15 years. We adjusted mean differences for baseline characteristics. Analyses were by intention to treat. The SOS study is registered with ClinicalTrials.gov, number NCT01479452.
Between Sept 1, 1987, and Jan 31, 2001, 2010 adults who had bariatric surgery and 2037 who were treated conventionally were enrolled into the SOS study. In this study, we followed up 4030 patients (2836 who were euglycaemic; 591 who had prediabetes; 603 who had diabetes). Drug costs did not differ between the surgery and conventional treatment groups in the euglycaemic subgroup (surgery US$10 511 vs conventional treatment $10 680; adjusted mean difference –$225 [95% CI −2080 to 1631]; p=0·812), but were lower in the surgery group in the prediabetes ($10 194 vs $13 186; –$3329 [–5722 to −937]; p=0·007) and diabetes ($14 346 vs $19 511; –$5487 [–7925 to −3049]; p<0·0001) subgroups than in the conventional treatment group. Compared with the conventional treatment group, we noted greater inpatient costs in the surgery group for the euglycaemic ($51 225 vs $25 313; $22 931 [19 001–26 861]; p<0·0001), prediabetes ($58 699 vs $32 861; $27 152 [18 736–35 568]; p<0·0001), and diabetes ($61 569 vs $47 569; 18 697 [9992–27 402]; p<0·0001) subgroups. We noted no differences in outpatient costs. Total health-care costs were higher in the surgery group in the euglycaemic ($71 059 vs $45 542; $22 390 [17 358–27 423]; p<0·0001) and prediabetes ($78 151 vs $54 864; $26 292 [16 738–35 845]; p<0·0001) subgroups than in the conventional treatment group, whereas we detected no difference between treatment groups in patients with diabetes ($88 572 vs $79 967; $9081 [–1419 to 19 581]; p=0·090).
Total health-care costs were higher for patients with euglycaemia or prediabetes in the surgery group than in the conventional treatment group, but we detected no difference between the surgery and conventional treatment groups for patients with diabetes. Long-term health-care cost results support prioritisation of patients with obesity and type 2 diabetes for bariatric surgery.
AFA Försäkring and Swedish Scientific Research Council.
www red DiabetologNytt